Surgery Websites
Transplant Surgery »  Meet the Team »  Basic Scientists »  Rajalingam Raja, Ph.D., D(ABHI)
Rajalingam Raja, Ph.D., FRCPath., D(ABHI)

Rajalingam Raja, Ph.D., FRCPath., D(ABHI)

  • Professor of Surgery
  • Director, Immunogenetics and Transplantation Laboratory

Contact Information

UCSF Immunogenetics and Transplantation Laboratory
Department of Surgery, Box 0508
3333 California Street, Suite 150
San Francisco, CA 94143
415-476-3883 Phone
415-476-0379 Fax 
[email protected]
Open Popup

University of Madras, India. B.Sc., 1984

Bharathiyar University, India. M.Sc., 1988

University of Madras, India. M.Phil., 1989

All India Institute of Medical Sciences, India. Ph.D., 1996

  • Postdoctoral Fellow, Stanford University, Stanford 1997-2002

Dr. Rajalingam Raja serves as the Laboratory Director, Clinical Consultant and Technical Supervisor for the UCSF Immunogenetics and Transplantation Laboratory. Dr. Raja received his Ph.D. from the Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi. Six-years of pre-doctoral studies in HLA diversity, followed by six-years of post-doctoral research in NK cell immunogenetics at Stanford, plus eighteen-years of experience in clinical histocompatibility laboratory directorship in the high volume transplant centers at UCLA and UCSF have shaped Dr. Raja into one of the uniquely experienced investigators committed to the fields of histocompatibility, immunogenetics and transplant immunology.

  Confired By    
  • Prof. NK Mehra Oration Award 2016
  • Indian Society for Histocompatibility and Immunogenetics (ISHI)
  • 2016
  • Certificate of Qualification, Histocompatibility Laboratory Director
  • New York State Department of Health
  • 2012
  • Histocompatibility Laboratory Director
  • Department of Public Health, State of California
  • 2009
  • Clinical Immunology Training Award
  • 1996
  • Clinical Immunology Training Award
  • Federal of Immunological Societies of Asia-Oceania/International Union of Immunological Societies
  • 1996
  • Shakuntala Amir Chand prize for the best Ph.D. thesis in Biomedical Sciences in India
  • Indian Council of Medical Research (ICMR)
  • 1996
  • University First Rank in post-graduation (M.Sc.: Zoology, Biochemicstry, Molecular Biology)
  • Bharathiyar University, Coimbatore, India
  • 1988
  • Natural killer (NK) have been implicated in control and clearance of malignant and virally infected cells, regulation of adaptive immune responses, rejection of bone marrow transplants, autoimmunity and the maintenance of pregnancy. Human NK cells largely use a family of Human Leukocyte Antigen (HLA)-specific Killer cell Immunoglobulin-like Receptors (KIR) to recognize and respond to the unhealthy target cells. KIR and HLA loci are both polygenic and substantially polymorphic, and they map to distinct human chromosomes (Chromosomes 19 and 6, respectively).

    KIR and HLA gene families segregate independently, yielding many individuals who express KIR receptors for which they lack HLA class I ligands, and vice versa, thus creating human diversity in the number and type of KIR-HLA inherited gene pairs, which potentially could influence the health and disease status of a given individual. The overall goal of our research is to understand the diversity of KIR receptors, HLA ligands, and KIR-HLA gene combinations in populations and their relevance in human health and disease.

    Data provided by UCSF Profiles, powered by CTSI
    1. Roll GR, Bray RA, Cooper M, Eagar TN, Gebel HM, Vranic GM, Hitchman KMK, Houp J, Kamoun M, Killian J, Kim J, Kumar V, Levine M, Lovasik BP, Lunow-Luke T, Parsons RF, Pattanayak V, Ranch D, Shah A, Stock PG, Timofeeva OA, Trofe-Clark J, Wongjirad C, Yeh H, Yi S, Rajalingam R. COVID-19 infection and vaccination rarely impact HLA antibody profile in waitlisted renal transplant candidates- a multicenter cohort. Hum Immunol. 2023 Apr; 84(4):278-285. View in PubMed
    2. Raghav PK, Raghav A, Lathwal A, Saxena A, Mann Z, Sengar M, Rajalingam R. Experimental and clinical data analysis for identification of COVID-19 resistant ACE2 mutations. Sci Rep. 2023 02 09; 13(1):2351. View in PubMed
    3. Duan M, Nguyen DC, Joyner CJ, Saney CL, Tipton CM, Andrews J, Lonial S, Kim C, Hentenaar I, Kosters A, Ghosn E, Jackson A, Knechtle S, Maruthamuthu S, Chandran S, Martin T, Rajalingam R, Vincenti F, Breeden C, Sanz I, Gibson G, Eun-Hyung Lee F. Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses. bioRxiv. 2023 Jan 20. View in PubMed
    4. Calabrese DR, Chong T, Singer JP, Rajalingam R, Hays SR, Kukreja J, Leard L, Golden JA, Lanier LL, Greenland JR. CD16+ natural killer cells in bronchoalveolar lavage are associated with antibody-mediated rejection and chronic lung allograft dysfunction. Am J Transplant. 2023 01; 23(1):37-44. View in PubMed
    5. Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, Deuse T. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression. Nat Biotechnol. 2023 05; 41(5):717-727. View in PubMed
    6. View All Publications


    Site Directory